Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 18.09%, which has investors questioning if this is right ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.58%, which has investors questioning if this is right ...

TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Tonix Pharmaceuticals, known for its focus on central nervous system disorders and pain management, is also advancing TNX-102 SL, a product candidate for fibromyalgia management, with a PDUFA goal ...

Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.

Tonix Pharmaceuticals (NASDAQ:TNXP) was able to have its New Drug Application of TNX-102 SL for the treatment of patients with Fibromyalgia accepted by the FDA. Not only was this regulatory ...

TNX-102 (subcutaneous levosimendan), TNX-101 (IV levosimendan), the active metabolites of levosimendan (OR1896 and OR18955), and various combinations of cardiovascular drugs with levosimendan when ...

This significant rise was driven by a positive regulatory update for TNX-102 SL, the company's leading drug candidate. The FDA announced it would not require an advisory committee meeting to ...